A single dose of investigational tanruprubart resulted in rapid, sustained improvement in disability compared with placebo in ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...

This announcement was made alongside the reveal of positive Phase 3 results for Tanruprubart, a monoclonal antibody that can block C1q and can potentially halt neuroinflammation and nerve damage in ...

Former Beltrami jail nurse Michelle Skroch made her first appearance in court Friday. She’s charged with criminal neglect and ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

Annexon achieved primary endpoints in two Phase 3 studies for tanruprubart in treating Guillain-Barre Syndrome, setting the stage for a pre-BLA meeting ...

Annexon, Inc. (NASDAQ:ANNX) on Tuesday presented data for its late-stage targeted therapy, tanruprubart (formerly ANX005), ...